Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are Cannabis Sublingual Sprays Better Than Pills for Elderly Dementia Patients? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

For older adults living with dementia, the way a medicine is taken can make a significant difference to safety, effectiveness, and comfort. With increasing interest in medical cannabis, clinicians and caregivers often ask whether sublingual sprays (such as oromucosal THC:CBD formulations) are better suited than oral pills or capsules for elderly patients. 

According to NHS guidance, cannabis-based medicinal products (CBMPs) can only be prescribed by specialist doctors for a limited number of conditions, including multiple sclerosis and chemotherapy-related nausea but not for dementia.  

Can medical cannabis be accessed legally for women’s health?

Comparing Sublingual Sprays and Pills 

Sublingual cannabis sprays, such as those containing balanced THC and CBD (for example, Sativex), are absorbed through the lining of the mouth. This allows faster onset and easier dose control, typically within 15–45 minutes. Older adults with swallowing difficulties or those taking multiple medications may find sprays more manageable and less likely to cause digestive issues than pills. 

In contrast, oral capsules or tablets must pass through the digestive system, leading to slower and less predictable absorption. Effects can take one to two hours to appear, and metabolism through the liver may increase variability between individuals, particularly in frail or elderly patients. 

Studies such as Hermush et al., Frontiers in Medicine (2022) and Outen et al., PMC (2021) note that sublingual oils and sprays allow more precise titration, an important factor when managing dementia symptoms such as agitation or restlessness. Still, both routes remain experimental in this population, with limited and inconsistent results. 

Regulatory And Safety Considerations 

The NICE guidance on cannabis-based medicinal products (NG144, 2025) (NICE NG144) does not recommend cannabis for dementia-related symptoms outside research trials. Likewise, the Alzheimer’s Society UK (Cannabis, CBD oil and dementia) cautions that side effects such as dizziness, confusion, and drowsiness are common, especially in older adults and with THC-containing products. 

Clinical Bottom Line 

  • Sublingual sprays may allow faster onset and easier dose adjustments than pills. 
  • Pills have slower absorption and may cause variable effects in older adults. 
  • No formulation has proven superior for treating dementia symptoms. 
  • NICE and NHS do not endorse cannabis for dementia except in research settings. 
  • Any use should be specialist-supervised and limited to regulated medical products. 

About AlleviMed 

AlleviMed provides clear educational information about how medical cannabis eligibility is assessed within UK regulatory frameworks. It helps patients, caregivers, and professionals understand the approved pathways for cannabis-based treatments, supporting safe, evidence-informed decisions. 

Takeaway 

For elderly people with dementia, sublingual cannabis sprays may appear more practical than pills due to faster action and easier dosing. However, the evidence remains limited, and neither form has been proven effective or safe for dementia symptoms. NICE and NHS guidance advise against cannabis prescribing outside research. Anyone considering its use should do so only under specialist medical supervision and within legal frameworks. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories